证券代码：603858 证券简称：步长制药 公告编号：2025-137 山东步长制药股份有限公司 关于控股子公司拟对外投资设立子公司的进展公告 乙方：零医数术（陕西） （二）合资公司的设立 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 根据山东步长制药股份有限公司（以下简称"公司"或"步长制药"）总体 发展规划，为促进公司控股子公司山东步长传方药业有限公司（以下简称"山东 步长传方"）的经营发展，山东步长传方拟与零医数术（陕西）互联网科技有限 公司（以下简称"零医数术（陕西）"）共同投资设立新公司陕西步长医数药业有 限公司（暂定名，最终名称以工商注册登记为准）（以下简称"陕西步长医数"）。 陕西步长医数注册资本 500 万元,山东步长传方出资 400 万元，持股比例 80%,零 医数术（陕西）出资 100 万元，持股比例 20%。本次投资完成后，陕西步长医数 将会纳入公司合并报表范围。具体内容详见公司 2025 年 6 月 21 日披露于上海证 券交易所网站（www.sse.com.cn）的《关于控股子公司 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-138 2024 年 11 月 27 日，山东步长制药股份有限公司（以下简称"公司"或"步 长制药"）召开第五届董事会第九次会议，审议通过了《关于控股子公司减少注 册资本暨关联交易的议案》，同意公司控股子公司步长（广州）医学诊断技术有 限公司（以下简称"步长医学诊断"）全体股东（包括公司、公司关联人及其他 股东）对步长医学诊断进行减资。本次减资完成后，步长医学诊断的注册资本将 由 5,882.3529 万元减少至 1,186.8245 万元。具体内容详见公司 2024 年 11 月 29 日披露于上海证券交易所网站（www.sse.com.cn）的《关于控股子公司减少 注册资本暨关联交易的公告》（公告编号：2024-152）。 2025 年 6 月 17 日，步长医学诊断与有关各方正式签署了《减资协议》。具体 内容详见公司 2025 年 6 月 18 日披露于上海证券交易所网站（www.sse.com.cn） 的《关于控股子公司减少注册资本暨关联交易的进展公告》（公告编号：2025-116）。 二、本次交易的进展 近日，步长医学诊断已完成工商变更 ...

Core Viewpoint - Recently, Buchang Pharma (603858.SH) announced that its subsidiary, Zhejiang Tianyuan Biopharmaceutical Co., Ltd., has received the drug registration certificate for the quadrivalent influenza virus split vaccine from the National Medical Products Administration, making it the 9th certified company for this vaccine in China [1] Group 1: Vaccine Approval and Market Potential - The quadrivalent influenza vaccine is a key step in Buchang Pharma's strategy to expand from traditional Chinese medicine into biopharmaceuticals and vaccines [1] - Research indicates that approximately 84 million to 144 million people in China contract influenza annually, highlighting the significant market potential for vaccination [1] - The current vaccination rate for influenza in China is low, indicating substantial room for growth [1] Group 2: Timing and Production Advantages - The approval of the vaccine is timely, as the peak influenza season occurs from November to March, and vaccination requires 2-4 weeks to develop protective antibodies [1] - The vaccine was approved in July, allowing ample time for production and market distribution to meet the upcoming vaccination peak [1] Group 3: Product Details - The quadrivalent influenza virus split vaccine contains 15μg of each type of influenza virus hemagglutinin per 0.5ml dose, and is classified as a prescription biological product [3][4] - The vaccine is manufactured by Zhejiang Tianyuan Biopharmaceutical Co., Ltd., located in Hangzhou, Zhejiang Province [3][4] Group 4: R&D Investment and Commitment - As of June 30, 2025, Buchang Pharma has invested approximately 126 million yuan in the vaccine project, reflecting its commitment to new drug development [7] - The company emphasizes strict quality control throughout the drug development, manufacturing, and sales processes, showcasing its technical capabilities [7] Group 5: Shareholder Returns and Corporate Responsibility - Buchang Pharma has consistently returned value to shareholders through cash dividends and share buybacks, having paid out a total of 9.183 billion yuan since its listing [8] - The company plans to reduce its registered capital by repurchasing 44.8536 million shares, which is expected to enhance per-share value and stabilize stock prices [8] - Buchang Pharma has contributed over 32 billion yuan in taxes since its establishment, demonstrating its commitment to social responsibility and local economic development [8]

证券代码：603858 证券简称：步长制药 公告编号：2025-136 山东步长制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）利润总额：40,397.28 万元；归属于母公司所有者的净利润 23,141.67 万元；归属于母公司所有者的扣除非经常性损益的净利润：22,098.18 万元。 （二）每股收益：0.2110 元。 三、本期业绩预增的主要原因 公司本期归属于母公司所有者的净利润及归属于母公司所有者的扣除非经 常性损益的净利润较上年同期大幅上升，主要原因如下：1.本期药品的销售规模 同比增长；2.主要产品的生产成本同比下降；3.公司收购通化谷红制药有限公司、 吉林天成制药有限公司时，形成的评估增值对应的摊销额至 2024 年末摊销完毕， 摊销额同比减少。 一、本期业绩预计情况 经山东步长制药股份有限公司（以下简称"公司"）财务部门初步测算，预 计 2025 年半年度实现归属于母公司所有者的净利润约为 48,800 万元到 70,800 万元，与上年同期相比，将增加 25,658. ...

[Current Period Performance Forecast](index=1&type=section&id=Item%20I.%20Current%20Period%20Performance%20Forecast) The company expects significant performance growth in H1 2025, with net profit attributable to shareholders projected to rise by over 110% | Indicator | Estimated Amount (million RMB) | YoY Change (million RMB) | YoY Growth Rate | | :--- | :--- | :--- | :--- | | **Net Profit Attributable to Parent Company Shareholders** | 488.00 to 708.00 | +256.58 to +476.58 | +110.88% to +205.94% | | **Net Profit Excluding Non-Recurring Gains/Losses** | 476.00 to 702.00 | +255.02 to +481.02 | +115.40% to +217.67% | - The performance forecast applies to situations where profitability is achieved, with net profit increasing by over 50% compared to the same period last year[5](index=5&type=chunk) - This performance forecast is a preliminary estimate by the company's finance department and has not been audited by a certified public accountant[5](index=5&type=chunk)[6](index=6&type=chunk) [Prior Period Performance Overview](index=2&type=section&id=Item%20II.%20Prior%20Period%20Performance%20Overview) The 2024 H1 performance serves as a benchmark, reporting net profit attributable to parent company shareholders at RMB 231.42 million | Indicator | 2024 H1 Amount | | :--- | :--- | | Total Profit | 403.97 million RMB | | Net Profit Attributable to Parent Company Shareholders | 231.42 million RMB | | Net Profit Excluding Non-Recurring Gains/Losses | 220.98 million RMB | | Earnings Per Share | 0.2110 RMB | [Key Reasons for Current Period Performance Growth](index=2&type=section&id=Item%20III.%20Key%20Reasons%20for%20Current%20Period%20Performance%20Growth) Performance growth is driven by expanded drug sales, reduced production costs, and significantly lower intangible asset amortization - Drug sales volume achieved year-over-year growth[9](index=9&type=chunk) - Production costs for key products decreased year-over-year[9](index=9&type=chunk) - Amortization of appraisal increments from the acquisitions of Tonghua Guhong Pharmaceutical and Jilin Tiancheng Pharmaceutical completed by the end of 2024, leading to a year-over-year reduction in current period amortization expenses[9](index=9&type=chunk) [Risk Warning](index=2&type=section&id=Item%20IV.%20Risk%20Warning) The company confirmed with its annual audit firm that no significant uncertainties affect the forecast's accuracy - The company has communicated with its annual audit firm regarding the performance forecast and found no significant uncertainties affecting its accuracy[10](index=10&type=chunk) [Other Relevant Information](index=2&type=section&id=Item%20V.%20Other%20Relevant%20Information) The company emphasizes this is preliminary data; final figures will be in the official 2025 semi-annual report - The forecast data is preliminary, and the final financial figures will be based on the company's officially disclosed 2025 semi-annual report[11](index=11&type=chunk)

步长制药（603858）公告，预计2025年半年度实现归属于母公司所有者的净利润约为4.88亿元到7.08亿 元，与上年同期相比，将增加2.57亿元到4.77亿元，同比增加110.88%到205.94%。预计2025年半年度实 现归属于母公司所有者的扣除非经常性损益的净利润约为4.76亿元到7.02亿元，与上年同期相比，将增 加2.55亿元到4.81亿元，同比增加115.40%到217.67%。 ...

Transaction Overview - The company plans to transfer 1% equity stakes in nine subsidiaries to Xie Jihui as part of its strategy to develop and integrate its health industry [1] - The subsidiaries involved in the equity transfer include Ningbo Buchang Trading Co., Ltd., Shandong Buchang Cosmetics Biotechnology Co., Ltd., Shandong Buchang Dingsheng Pharmaceutical Co., Ltd., Shandong Buchang Chuanfang Pharmaceutical Co., Ltd., Shandong Buchang Youpin Medical Technology Co., Ltd., Jinan Buchang Chicheng Trading Co., Ltd., Jinan Buchang Caigan Trading Co., Ltd., Jinan Buchang Yingxi Trading Co., Ltd., and Jinan Buchang Zhongfu Trading Co., Ltd. [1] Progress of the Transaction - The company and Xie Jihui have signed the equity transfer agreement and a supplementary cooperation agreement [2] - The transfer price for the equity stakes is set at 0 yuan, with Xie Jihui assuming the obligation for the paid-in capital of the transferred equity [2][3] - The completion of the equity transfer will be recognized upon the completion of the industrial and commercial change registration [3] Transitional Period and Responsibilities - A transitional period will be established from the signing of the agreement until the completion of the equity transfer, during which profits and losses will be shared according to the equity ratio [4] - Any breach of the agreement will require the breaching party to remedy the situation within 30 days of notification [4] Supplementary Agreement - The supplementary agreement clarifies that after the equity transfer, the company will no longer hold any rights or obligations related to the transferred equity [5] - The supplementary agreement and the original cooperation agreement together constitute the complete documentation for the transaction [5]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 为大力发展和整合山东步长制药股份有限公司（以下简称"公司"或"步长 制药"）大健康产业，公司拟将持有的 9 家控股子公司宁波步长贸易有限公司、 山东步长药妆生物科技有限公司（以下简称"山东步长药妆"）、山东步长鼎晟 药业有限公司（以下简称"山东步长鼎晟"）、山东步长传方药业有限公司（以 下简称"山东步长传方"）、山东步长优品医疗科技有限公司、济南步长驰骋商 贸有限公司（以下简称"济南步长驰骋"）、济南步长财淦商贸有限公司（以下 简称"济南步长财淦"）、济南步长瀛玺商贸有限公司（以下简称"济南步长瀛 玺"）、济南步长众福商贸有限公司（以下简称"济南步长众福"）各 1%股权（以 下简称"目标股权"）转让给谢继辉。具体内容详见公司 2025 年 5 月 21 日披露 于上海证券交易所网站（www.sse.com.cn）的《关于拟转让控股子公司股权的公 告》（公告编号：2025-093）。 二、本次交易的进展 近日，公司与有关各方正式签署了关于山东步长药妆、山东步长鼎晟、山 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-135 山东步长制药股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、药品其他情况 四价流感病毒裂解疫苗主要用于刺激机体产生抗流行性感冒病毒的免疫力， 预防本毒株引起的流行性感冒。 经查询国家药品监督管理局网站，目前国内已上市四价流感病毒裂解疫苗的 厂家包括江苏金迪克生物技术股份有限公司、华兰生物疫苗股份有限公司、北京 科兴生物制品有限公司、安徽智飞龙科马生物制药有限公司、武汉生物制品研究 所有限责任公司、复星雅立峰（大连）生物制药有限公司、长春生物制品研究所 有限责任公司、深圳赛诺菲巴斯德生物制品有限公司。 截至 2025 年 6 月 30 日，公司在四价流感病毒裂解疫苗项目上投入的研发费 用约为 12,582.62 万元。 三、风险提示 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安 全，本次获得四价流感病毒裂解疫苗的《药品注册证书》有利于公司优化产品结 构，继续保持稳定的生产能力，满足 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for its quadrivalent influenza virus split vaccine, which is intended to stimulate the immune response against influenza viruses [1] Group 1 - The vaccine is primarily used to prevent influenza caused by the relevant strains of the virus [1] - The company has invested approximately 126 million yuan in research and development for the quadrivalent influenza virus split vaccine project as of June 30, 2025 [1]